Biora Therapeutics Announces Successful Completion Of Device Performance Study In Ulcerative Colitis Patients For Its Targeted Therapeutics Platform
Biora Therapeutics Announces Successful Completion Of Device Performance Study In Ulcerative Colitis Patients For Its Targeted Therapeutics Platform
Biora治療公司宣佈成功完成其靶向治療平臺在潰瘍性結腸炎患者中的設備性能研究
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule (DDS) in Subjects with Ulcerative Colitis in a Fasted State.
正在重塑治療方法的生物技術公司Biora治療公司(納斯達克代碼：BIOR)今天宣佈了其最近完成的PM-602研究的主要結果：一項旨在評估禁食狀態下潰瘍性結腸炎患者藥物輸送系統膠囊(DDS)的定位和輸送功能的閃爍研究。